[HTML][HTML] Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study
M Reck, A Anthoney, AR Hanauske, E Dean… - Annals of oncology, 2010 - Elsevier
Background Erlotinib and pemetrexed are approved single agents for second-line treatment
of non-small-cell lung cancer (NSCLC) and, in combination, have shown synergistic …
of non-small-cell lung cancer (NSCLC) and, in combination, have shown synergistic …
Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study
M Ranson, M Reck, A Anthoney… - Annals of …, 2010 - annalsofoncology.org
Background Erlotinib and pemetrexed are approved single agents for second-line treatment
of non-small-cell lung cancer (NSCLC) and, in combination, have shown synergistic …
of non-small-cell lung cancer (NSCLC) and, in combination, have shown synergistic …
Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study
M Ranson, M Reck, A Anthoney… - Annals of oncology …, 2010 - pubmed.ncbi.nlm.nih.gov
Background Erlotinib and pemetrexed are approved single agents for second-line treatment
of non-small-cell lung cancer (NSCLC) and, in combination, have shown synergistic …
of non-small-cell lung cancer (NSCLC) and, in combination, have shown synergistic …
[PDF][PDF] Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study
M Ranson, M Reck, A Anthoney, AR Hanauske… - Annals of …, 2010 - academia.edu
Background: Erlotinib and pemetrexed are approved single agents for second-line treatment
of non-small-cell lung cancer (NSCLC) and, in combination, have shown synergistic …
of non-small-cell lung cancer (NSCLC) and, in combination, have shown synergistic …
[引用][C] Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study
M RANSON, M RECK, A ANTHONEY… - Annals of …, 2010 - pascal-francis.inist.fr
Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung
cancer (NSCLC): a phase I dose-finding study CNRS Inist Pascal-Francis CNRS Pascal …
cancer (NSCLC): a phase I dose-finding study CNRS Inist Pascal-Francis CNRS Pascal …
Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.
MR Ranson, M Reck, A Anthoney, AR Hanauske… - 2010 - christie.openrepository.com
BACKGROUND: Erlotinib and pemetrexed are approved single agents for second-line
treatment of non-small-cell lung cancer (NSCLC) and, in combination, have shown …
treatment of non-small-cell lung cancer (NSCLC) and, in combination, have shown …
Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.
M Ranson, M Reck, A Anthoney… - Annals of Oncology …, 2010 - europepmc.org
Background Erlotinib and pemetrexed are approved single agents for second-line treatment
of non-small-cell lung cancer (NSCLC) and, in combination, have shown synergistic …
of non-small-cell lung cancer (NSCLC) and, in combination, have shown synergistic …
Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.
M Ranson, M Reck, A Anthoney… - 1569 …, 2010 - escholar.manchester.ac.uk
BACKGROUND: Erlotinib and pemetrexed are approved single agents for second-line
treatment of non-small-cell lung cancer (NSCLC) and, in combination, have shown …
treatment of non-small-cell lung cancer (NSCLC) and, in combination, have shown …
Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): A phase I dose-finding study
M Ranson, M Reck, A Anthoney… - Annals of …, 2010 - research.manchester.ac.uk
Background: Erlotinib and pemetrexed are approved single agents for second-line treatment
of non-small-cell lung cancer (NSCLC) and, in combination, have shown synergistic …
of non-small-cell lung cancer (NSCLC) and, in combination, have shown synergistic …